Fibrinopeptide a (FPA) in patients with acute myocardial infarction

Johnsson, Hans; Orinius, E.; Paul, Christer

doi:10.1016/0049-3848(79)90286-x

Cited by 51 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 High incidence of vascular involvement is seen in various cardiovascular disorders, and high FPA levels could be correlated with an increased risk of thrombosis. This marker has been found to be of value for patients with suspected myocardial infarc tion 20 in which levels are related to the severity of infarction.…”

Section: Clinical Applications Of Fpamentioning

confidence: 99%

Development and Performance Characteristics of a Competitive Enzyme Immunoassay for Fibrinopeptide A

Amiral¹,

Walenga²,

Fareed³

1984

Semin Thromb Hemost

View full text Add to dashboard Cite

A simple nonisotopic method for the quantitation of FPA in biologic samples has been developed utilizing a competitive enzyme immunoassay technique. The performance characteristics of these assays have been investigated in both the experimental and clinical settings and were found to be satisfactory for the routine clinical application. This method is comparable to a commercially available RIA kit (Mallinckrodt, St. Louis, MO) in both the clinical and normal samples. This assay can be used in the diagnosis of hypercoagulable states associated with various diseases. Subclinical activation of coagulation can be readily assessed when the global tests, such as the prothrombin time, partial thromboplastin time, and thrombin time, have no value. This test is of value in the monitoring of the newer antithrombotic agents, such as the low molecular weight heparin fractions that do not effect the global assays, such as the partial thromboplastin time. Similarly, the risk of thrombosis associated with the use of procoagulant therapy, such as the activated prothrombin complex concentrates, can be readily assessed using this assay. It is proposed that the FPA measurement may also provide useful information on the quality control of various plasma-based therapeutic products, such as plasma concentrates or activated prothrombin complex concentrates. FPA generation tests are currently proposed for the screening of antithrombotic and prohemostatic agents.

show abstract

Section: Clinical Applications Of Fpamentioning

confidence: 99%

Development and Performance Characteristics of a Competitive Enzyme Immunoassay for Fibrinopeptide A

Amiral¹,

Walenga²,

Fareed³

1984

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…10 All these studies were limited to the early phase of infarction and did not exceed a period of 48 hours. Only Johnsson et al 4 extended their observations until the eighth day after infarction and noticed on that day an elevation of mean FPA levels in the seven patients studied.…”

mentioning

confidence: 99%

Persistent generation of thrombin after acute myocardial infarction.

Szczeklik¹,

Dropiński²,

Radwan³

et al. 1992

Arterioscler Thromb

View full text Add to dashboard Cite

During the acute phase of myocardial infarction, the generation of thrombin is reflected in the sudden rise of fibrinopeptide A (FPA) and the thrombin-antithrombin III (TAT) complex in blood. We have systematically determined the FPA and TAT plasma concentrations over a period of 14 days after acute myocardial infarction in 100 patients. Mean levels of both thrombin markers were the highest on admission, remained elevated over the following few days, and then gradually declined after day 5. Still, by the end of the first week two thirds of the patients had distinctly elevated TAT and FPA levels, and by the end of the second week such an abnormality was present in half of them. Continuous intravenous heparin infusion at a dose of 20,000 units/day, administered for 1 week to patients who had either received (n=21) or not received (n=17) streptokinase, led to a significant depression (p<0.05) of thrombin markers over the first 48 hours, an effect that did not persist over the subsequent days of treatment In patients not assigned to heparin treatment, those in heart failure had significantly (p<0.05) higher mean TAT and FPA values on days 3,5, and 7 compared with patients in whom heart failure was absent Infarct extension, pulmonary embolism, and death were also associated with a rise in one or both thrombin markers, often preceding the onset of clinical symptoms. Thrombinogenesis was not accompanied by changes in mean plasma concentrations of prothrombin, antithrombin III, or a^-macroglobulin. It is suggested that thrombin was continuously released to the plasma from coronary or extracoronary thrombi undergoing lysis and subsequent rebuilding. Thus, thrombin generation that extends beyond the acute phase of myocardial infarction indicates an increased risk to the patients and might call for more anticoagulation, angioplasty, or the use of new antithrombotic agents.

show abstract

“…A comparable pattern was previously found (22). Plasma coagulation is activated during myocardial infarction as shown sensitively by fibrinopeptide A production (13) or high molecular weight fibrin(ogen) complex (HMWFC) concentration (8). The changes in the parameters of coagulation and fibrinolysis measured in the present study are in close accordance with previous findings (1,11,14,20,30).…”

Section: Resultsmentioning

confidence: 99%

β‐Thromboglobulin in Acute Myocardial Infarction

Rasi

Torstila

Ikkala

1980

Journal of Internal Medicine

View full text Add to dashboard Cite

ABSTRACT. The plasma β‐thromboglobulin level was studied serially in 14 patients with acute myocardial infarction. In 7 patients the plasma β‐thromboglobulin was initially high. The most severely affected patients had the highest values. Three patients with a mild or moderate clinical course had a normal β‐thromboglobulin level at every stage. The remaining patients had a distinct pattern in the evolution of the plasma β‐thromboglobulin values. The initial phase was followed by a uniform fall during the first days and then by an increase. The highest values were in many cases measured at discharge. Platelet counts showed a similar pattern. Signs of activation of platelets were seen before changes in coagulation and fibrinolysis.

show abstract

Fibrinopeptide a (FPA) in patients with acute myocardial infarction

Cited by 51 publications

References 14 publications

Development and Performance Characteristics of a Competitive Enzyme Immunoassay for Fibrinopeptide A

Development and Performance Characteristics of a Competitive Enzyme Immunoassay for Fibrinopeptide A

Persistent generation of thrombin after acute myocardial infarction.

β‐Thromboglobulin in Acute Myocardial Infarction

Contact Info

Product

Resources

About